Vaxart Inc (NASDAQ:VXRT)
| 0.7125 Delayed Data As of Sep 22 |  +0.0014 / +0.20%Today’s Change | 0.56 Today|||52-Week Range 2.35 | -25.85% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $108.2M |
Company Description
Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.
Contact Information
Vaxart, Inc. 170 Harbor Way South San Francisco California 94080 |
Employees
Shareholders
| Mutual fund holders | 6.35% |
| Other institutional | 12.74% |
| Individual stakeholders | 1.83% |
Top Executives
| Andrei Floroiu | President, Chief Executive Officer & Director |
| Phillip Eric Lee | Chief Financial Officer |
| Sean N. Tucker | Chief Scientific Officer & Senior Vice President |
| James F. Cummings | Chief Medical Officer |
| Raymond D. Stapleton | Chief Technology Officer |
